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Summary
 
Lentiviral vectors have been advocated to be effective vehicles for the delivery and stable ex-
pression of genes in nondividing primary cells. However, certain cell types, such as resting T
lymphocytes, are resistant to infection with HIV-1. Establishing parameters for stable gene de-
livery into primary human lymphocytes and approaches to overcome the resistance of resting T
cells to HIV infection may permit potential gene therapy applications, genetic studies of pri-
mary cells in vitro, and a better understanding of the stages of the lentiviral life cycle. Here we
demonstrate that an HIV-1–derived vector can be used for stable delivery of genes into acti-
vated human T cells as well as natural killer and dendritic cells. Remarkably, a sizeable fraction
of resting T cells was stably transduced with the HIV-1 vector when cultured with the cyto-
kine interleukin (IL)-2, IL-4, IL-7, or IL-15, or, at a lower level, with IL-6, in the absence of
any other stimuli. Resting T cells stimulated with these cytokines could also be infected with
replication-competent HIV-1. To test the utility of this system for performing structure–func-
tion analysis in primary T cells, we introduced wild-type as well as a mutant form of murine
CD28 into human T cells and showed a requirement for the CD28 cytoplasmic domain in co-
stimulatory signaling. The ability to stably express genes of interest in primary T cells will be a
valuable tool for genetic and structure–function studies that previously have been limited to
transformed cell lines. In addition, the finding that cytokine signals are sufficient to permit
transduction of resting T cells with HIV may be relevant for understanding mechanism of
HIV-1 transmission and pathogenesis.
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R
 
etroviruses have the ability to integrate their genetic
material into target cell genomes and thus may be es-
pecially useful for delivering genes into primary cells for the
purpose of somatic gene therapy (1–3). Retroviral vectors
derived from oncoretroviruses such as murine leukemia vi-
rus (MLV)
 
1
 
 integrate strictly in cycling cells, due to an ap-
parent inability to translocate the viral genome across an in-
tact nuclear envelope (4–7). In contrast, lentiviruses such as
HIV-1 can integrate their genetic material into the genome
of nonproliferating cells such as macrophages or cell cycle–
arrested transformed cell lines (7–10). The ability of HIV-1
to transduce nonmitotic cells has been ascribed to three
karyophilic virion proteins, Integrase, Matrix, and Vpr,
each of which can interact with the nuclear import ma-
chinery to transport the HIV-1 preintegration complex
into the nucleus (11–17). However, resting T cells are not
susceptible to productive infection with HIV-1. Although
virus can enter into these cells, integration into the host cell
genome is not observed (18–25).
Vectors derived from the HIV-1 genome recently have
been shown to transduce terminally differentiated nondivid-
ing cells, both in vitro and
 
 
 
in vivo, enabling long-term ex-
pression of transduced gene products (26–33). These vectors
were engineered to be replication-incompetent by deletion
of the envelope glycoprotein gene (
 
env
 
) and the accessory
genes 
 
vif
 
,
 
 vpr
 
,
 
 vpu
 
,
 
 
 
and 
 
nef
 
. A heterologous envelope glyco-
protein expressed in trans is used for production of pseudo-
typed viral particles. The vesicular stomatitis virus glycoprotein
(VSV-G) has been used widely in pseudotyping HIV parti-
cles because of its broad host range and the ability of the
pseudotyped particles to be concentrated by ultracentrifuga-
tion without significant loss of infectivity (34–36).
In addition to their potential applications for therapeutic
delivery of genes into primary human cells, lentiviral vec-
 
1
 
Abbreviations used in this paper:
 
 BrdU, bromodeoxyuridine; DC, dendritic
cell; EGFP, enhanced GFP; GFP, green fluorescent protein; h, human;
HDV, HIV-1–derived vector; IRES, internal ribosome entry site; m,
murine; MLV, murine leukemia virus; MOI, multiplicity of infection;
PLAP, placental alkaline phosphatase; VSV-G, vesicular stomatitis virus
glycoprotein. 
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tors may have other practical applications. Stable introduc-
tion of exogenous wild-type or mutant genes into primary
cells such as T lymphocytes would be particularly valuable
for dissecting intracellular signaling pathways in these cells,
because this area of investigation thus far has been confined
to transformed cell lines. Genetic manipulation of resting T
cells in vitro could also provide novel approaches for study-
ing their activation and maturation requirements. More-
over, these vector systems would be valuable in dissecting
the cellular requirements for the HIV-1 life cycle, such as
integration or transcription in primary T cells.
Toward these objectives, we have used a replication-
defective, multiply attenuated HIV-1 vector system that can
very efficiently and stably transduce preactivated primary T
lymphocytes and myeloid lineage cells. Remarkably, resting
human T cells of both naive and memory subsets were also
stably transduced with HIV when stimulated with IL-2,
IL-4, IL-6, IL-7, or IL-15. Moreover, resting T cells treated
with cytokines were rendered permissive to infection with
replication-competent HIV-1. To demonstrate the feasibility
of performing structure–function studies with primary T
cells, we have used this vector system to show that wild-type
murine CD28, but not the cytoplasmically truncated form,
can transmit costimulatory signals in transduced primary hu-
man T cells. Our results show that this HIV vector system
can be used for genetic manipulation of primary T lympho-
cytes and suggest that cytokine signals may play an important
role in HIV-1 infection of resting T cells in vivo.
 
Materials and Methods
 
Plasmids and DNA Constructions.
 
The modified HIV-1 trans-
duction vector was derived from pHIV-PLAP, which has a back-
bone of the HIV-1 NL4-3 provirus with a frameshift in 
 
env
 
 and
substitution of the human placental alkaline phosphatase (PLAP)
gene in place of the 
 
nef
 
 gene (37). This vector was further manip-
ulated to remove 
 
vif
 
,
 
 vpr
 
,
 
 vpu
 
, and 
 
env 
 
genes as previously de-
scribed (38). Genes of interest were introduced between the 5
 
9
 
NotI and 3
 
9
 
 XhoI sites within the 
 
nef
 
 open reading frame, thus
replacing the PLAP cDNA. An additional EcoRI site was intro-
duced 3
 
9
 
 of the NotI site to facilitate subcloning of different cDNAs.
The murine (m)CD28 cDNA (gift of J. Allison, University of
California, Berkeley, CA) was subcloned into pBluescript (Strat-
agene) and the cytoplasmic mutant version was prepared by site-
directed mutagenesis techniques through overlap PCR amplifica-
tion using mutated oligonucleotides as previously described
(39). All constructs were verified by DNA sequencing and were
subcloned into the HIV vector. The mCD4 cDNA has been de-
scribed previously (40). The enhanced green fluorescent protein
(EGFP), purchased from Clontech, was subcloned into the HIV
vector by introducing 5
 
9
 
 NotI and 3
 
9
 
 XhoI sites through PCR
amplification. A bicistronic construct was prepared by ligation of
the EGFP to the 3
 
9
 
 end of the encephalomyocarditis virus inter-
nal ribosomal entry site (IRES) sequence (41) and was similarly
subcloned into the EcoRI-XhoI sites within the HIV vector. A
GFP-encoding, replication-competent HIV-1 provirus was con-
structed by subcloning EGFP in place of the 
 
nef
 
 gene in the R5-
tropic HIV-1 (BAL) backbone. The EGFP was also subcloned
into the MLV-derived vector, pMX, provided by Dr. Toshio Ki-
tamura (Tokyo University, Tokyo, Japan).
 
Preparation of Primary Human T Cell Lines.
 
PBMCs were sep-
arated from buffy coats of healthy donors (New York Blood
Bank) through Ficoll-Hypaque (Pharmacia, Sweden). Monocytes
were removed by plastic adherence for 2 h at 37
 
8
 
C. To obtain
highly purified resting CD4
 
1
 
 and CD8
 
1
 
 T cells, PBMCs de-
pleted of monocytes were incubated with anti-CD4 or anti-CD8
conjugated with Dynabeads (Dynal, Norway) at a 1:4 target/bead
ratio. After 30 min of incubation at 4
 
8
 
C and continuous shaking,
the bead-bound cells were recovered using a magnet (Dynal).
The bead-bound cells were then washed at least four times to re-
move unbound cells and the CD4
 
1
 
 or CD8
 
1
 
 cells were detached
from the beads using Detachabead (Dynal) according to the man-
ufacturer’s instructions. These cells were incubated with anti–
HLA-DR and anti-CD69 antibodies, and then by Dynabeads
conjugated with goat anti–mouse IgG, followed by magnetic re-
moval of bead-bound preactivated cells. This purification proto-
col typically resulted in 99.5% purity of positively selected cells,
as determined by postpurification FACS
 
®
 
 analysis. In some ex-
periments, CD4 cells were negatively sorted into CD45RA
 
1
 
RO
 
2
 
and CD45RO
 
1
 
RA
 
2
 
 subsets by incubating with anti-CD45RO
and anti-CD45RA antibodies, respectively, followed by anti–mouse
IgG Dynabead separation as described above. B and NK cells
were purified by pre-incubating the cells with purified anti-CD19
(Becton Dickinson) or hybridoma supernatants of anti–human
(h)CD16 (American Type Culture Collection [ATCC]), respec-
tively, followed by magnetic separation using Dynabead-conju-
gated goat anti–mouse antibody. Bead-conjugated cells were then
cultured at 37
 
8
 
C for 2 h and separated from released beads by a
magnet (Dynal). The culture media used in all experiments was
RPMI 1640 (GIBCO BRL) supplemented with 10% FCS (Hy-
clone), penicillin (50 U/ml; GIBCO BRL), streptomycin (50
 
m
 
g/ml), sodium pyruvate (1 mM; GIBCO BRL), and glutamine
(2 mM; GIBCO BRL). T cell lines were prepared by activation of
purified resting T cells with allogeneic PBMCs, treated with 50
 
m
 
g/ml mitomycin C (Sigma Chemical Co.) for 30 min at 37
 
8
 
C
and 5 
 
m
 
g/ml PHA (Sigma Chemical Co.). Alternatively, T cells
were activated by cross-linking with plate-bound anti-CD3 anti-
body (OKT-3) and soluble anti-hCD28 antibody (PharMingen).
Cells were split 3 d after activation, expanded, and maintained in
culture media supplemented with 200 U/ml recombinant IL-2
(Chiron). Culture of T cells with cytokine combinations has been
described previously (42, 43). All cytokines were purchased from
Genzyme or R&D Systems. Macrophages were differentiated in
vitro after adherence to plastic. Dendritic cells (DCs) were gener-
ated as previously described (44). Activation of human B cells was
performed by noncognate stimulation with activated T cells as
previously described (42). The EBV-transformed B cell line was
generated by infection of PBMCs with supernatants from the
B95-8 cell line (ATCC) in the presence of 1 
 
m
 
g/ml Cyclosporin
A (Sigma Chemical Co.).
 
Virus Production and Infections.
 
Replication-incompetent HIV
particles pseudotyped with VSV-G were generated by calcium
phosphate transfection of HEK-293T cells (ATCC) with 20 
 
m
 
g
of proviral HIV vector and 12 
 
m
 
g of pL-VSV-G plasmid (36) per
3 
 
3
 
 10
 
6
 
 cells seeded on 10-cm plates. The transfection media was
replaced after 8 h with fresh DMEM supplemented with 10%
FCS. Supernatants were collected at 48 h after transfection. The
virus-containing supernatants were centrifuged for 10 min at
1,200 rpm to remove cells, then passed through 0.4-
 
m
 
m filters to
remove fine debris. Supernatants either were used immediately
for infections or were frozen in aliquots at 
 
2
 
80
 
8
 
C. The viral ti-
ters were determined by infection of the human T cell line
Hut78 with serially diluted virus supernatant. Typically, viral ti- 
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ters had a range of 3–10 
 
3
 
 10
 
6
 
 infectious units (ifu)/ml. T cells
were infected at a multiplicity of infection (MOI) of 10–20 in 24-
well plates in the presence of 10 
 
m
 
g/ml polybrene (Sigma Chemi-
cal Co.). After an additional day of culture with virus supernatants,
cells were washed or sedimented through Ficoll and resuspended in
fresh culture media. R5-tropic replication-competent viruses were
prepared similarly by transfecting 293T cells, and titers of 2–5 
 
3
 
10
 
5
 
 ifu/ml were obtained. VSV-G–pseudotyped MLV-based vi-
ruses were similarly prepared by transfecting 293T cells with 12 
 
m
 
g
each of pMX.EGFP, pJK3 (expressing MLV 
 
gag
 
 and 
 
pol
 
 genes),
and pL-VSV-G as well as 3 
 
m
 
g of pCMV-Tat plasmids.
 
T Cell Costimulation.
 
Flat-bottomed 96-well microtiter plates
were coated for 2 h at 37
 
8
 
C with goat anti–mouse IgG (Caltag) at
20 
 
m
 
g/ml. Plates were washed twice with PBS and coated with
anti-CD3 (OKT3, purified from ascites; ATCC) at different con-
centrations for 2 h at 37
 
8
 
C. Wells were washed an additional two
times with PBS, and T cells at 10
 
5 
 
cells/well were added to plates.
Purified anti-mCD28 or anti-hCD28 antibodies (PharMingen)
were added to cultures at 1 
 
m
 
g/ml in a 150 
 
m
 
l final volume. After
48–64 h, cells were pulsed for 16 h with 1 
 
m
 
Ci of [
 
3
 
H]thymidine,
and [
 
3
 
H]thymidine incorporation was measured with a beta
counter (Wallac). To determine IL-2 production, culture super-
natants were collected 36 h after initiation of stimulation and IL-2
activity was assayed using the CTLL-2 indicator cell line (ob-
tained from ATCC). The proliferation of CTLL cells were deter-
mined by [
 
3
 
H]thymidine incorporation for the last 4 h of a 24-h
culture.
 
Cell Staining and Bromodeoxyuridine Incorporation.
 
Cells were
stained with the relevant antibody on ice for 30 min in PBS
buffer with 2% FCS and 0.1% sodium azide. Staining or GFP ex-
pression was analyzed on a FACScan
 
®
 
 using the CellQuest soft-
ware (Becton Dickinson). Live cells were gated based on forward
and side scatter. Cell sorting was performed at the New York
University Medical Center core facility using a Coulter fluores-
cence-activated cell sorter. The following antibodies with PE,
FITC, TC, or PercP conjugations were used for staining: anti-
mCD28, anti-mCD4, anti-hCCR5 and anti-hCXCR4 (Phar-
Mingen), anti-hCD4 and -hCD45RO (Caltag), anti-hCD3,
-hCD8, -hCD14, -hCD16, -hCD19, -hCD25, -hCD56, -hCD69,
-hCD45RA, and -hHLA-DR (all from Becton Dickinson). Bro-
modeoxyuridine (BrdU) incorporation was performed by cultur-
ing the cells with 10 
 
m
 
M BrdU (Sigma Chemical Co.) for the in-
dicated time. After washing in staining buffer, the cells were
permeabilized using FACS
 
®
 
 permeabilizing solution (Becton
Dickinson) and stained with anti-BrdU–PE (PharMingen) in the
presence of DNAse I (Sigma Chemical Co.). Analyses were per-
formed using a FACScan
 
®
 
.
 
Results
 
Stable Gene Transduction into Human Lymphocytes using an
HIV-1–derived Vector System.
 
To achieve stable gene ex-
pression in primary human T cells using an HIV-1–derived
vector (HDV) system, we used an NL4-3–based HIV-1
provirus that has deletions in the envelope glycoprotein
(
 
env
 
) gene and the accessory genes
 
 vif
 
,
 
 vpr
 
,
 
 vpu
 
, and 
 
nef
 
 (38).
The GFP gene was subcloned in place of the 
 
nef 
 
open read-
ing frame, and this vector was pseudotyped with the VSV-G
envelope to produce a high titer, replication-incompetent
virus. To determine the efficiency and stability of HIV-
1–mediated gene transduction, mitogen-activated T cells
were challenged with HDV-EGFP viruses at an MOI of
10–20. After 3 d in IL-2–containing medium, during
which time the cells continued to expand, the majority of
the T cells (
 
z
 
65%) expressed GFP (Fig. 1 A). The GFP
 
1
 
cells were then sorted by a FACS
 
®
 
 and subsequently ex-
panded in IL-2 with bimonthly PHA stimulation to de-
termine the stability of expression of the transduced gene.
High levels of GFP expression were detected in T cell lines
that were expanded in culture for up to 4 mo (Fig. 1 B).
The expression of the introduced gene was also stable in
individual T cell clones that were established from HDV–
transduced T cell lines (data not shown). Furthermore, it
was possible to introduce (sequentially or simultaneously)
three different genes (GFP, mCD28, and mCD4) into the
same cells while maintaining their long-term expression
(data not shown). Therefore, it is feasible to exploit the
HDV system to express multiple gene products within a
given primary T cell population.
Figure 1. Stable delivery and expression of genes in activated human T
cell subsets through the HDV system. Purified T cells were activated with
PHA and allogeneic feeder cells for 4 d and transduced with the HDV
system. (A) Activated primary hCD41 T cells were infected with HDV-
EGFP viruses and GFP expression was analyzed by a FACS® 3 d after in-
fection. (B) GFP1 T cells were sorted and expanded in culture with re-
peated mitogen stimulation and expression was assessed 2 wk and 4 mo
after infection. (C) GFP expression in CD41 and CD81 T cell lines 5 d
after HDV-IRES.EGFP infection. PI, post infection. 
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We next assessed the efficiency of HDV-mediated gene
transduction into different subsets of T cells. To increase
the sensitivity of detecting transduced cells, we constructed
a modified vector, HDV-IRES.EGFP. Both spliced and
unspliced transcripts encoded by this vector permit efficient
translation of EGFP through the IRES, resulting in up to
threefold higher expression levels (data not shown). CD4
 
1
 
and CD8
 
1
 
 T cell subsets were purified from PBMCs, acti-
vated with PHA, and infected with HDV-IRES.EGFP virus.
Analyses of GFP expression 5 d after infection consistently
demonstrated a higher transduction efficiency (indicated as
percentage of GFP expressing cells) of activated CD4
 
1
 
 T
cells relative to CD8
 
1
 
 cells (Fig. 1 C). Similar results were ob-
served in separate experiments with other reporter genes
and cells from different donors (data not shown).
Transduction efficiencies of other subsets of lymphoid
and myeloid lineage cells were also examined. Activated 
 
g/d
 
-
TCR
 
1
 
 T cells, IL-2–activated NK cells, and in vitro–
derived DCs were efficiently and stably transduced as
shown by GFP expression 2–3 wk after infection with
HDV-IRES.EGFP virus. However, we were unable to de-
tect transduction of resting B cells, B cells stimulated
through noncognate interaction with activated T cells, or B
cells cultured with IL-4, IL-2, or IL-6 (Fig. 2 and data not
 
shown). Interestingly, EBV-transformed B cells were sus-
ceptible to infection albeit at a lower efficiency than acti-
vated T cells (
 
z
 
20% of cells were transduced at comparable
MOI, data not shown). Freshly isolated monocytes were
also resistant to transduction using the HDV system but in
vitro differentiation into macrophages rendered them sus-
ceptible (data not shown).
 
Cytokine Stimulation of Resting T Cells Permits Infection
with HIV.
 
It is well established that HIV challenge of qui-
escent T cells is blocked before completion of reverse tran-
scription (22). We have shown that TCR-activated T cells
are very efficiently and stably transduced with the HDV
system. However, for many experimental applications it
would be desirable to transduce resting T cells in the ab-
sence of TCR-induced activation, without affecting their
differentiation state. To determine the parameters of resting
T cell infection, CD4
 
1
 
 and CD8
 
1
 
 T cells were purified
from PBMCs that were also negatively sorted for the acti-
vation markers HLA-DR and CD69. The purity of sorted
cells was 99.5% for CD4
 
1
 
 T cells and 95–98% for CD8
 
1
 
 T
cells, as determined by FACS
 
®
 
 analyses. The purified cells
were cultured overnight and the resting status of these cells
was confirmed by the negligible expression levels of activa-
tion molecules (HLA-DR and CD69) and the lack of cy-
cling cells (data not shown). These cells were then infected
with HDV-IRES.EGFP at an MOI of 
 
z
 
20. As expected,
we found very few T cells expressing GFP 5 d after infec-
tion (
 
,
 
0.3%), and concluded that freshly isolated resting T
cells are resistant to transduction with the HDV system.
Certain cytokines, such as IL-2, IL-4, IL-7, or proinflam-
matory cytokines, such as TNF-
 
a
 
 or IL-6, have been shown
to potentiate HIV replication in vitro (45, 46). Some of
these cytokines (IL-2, IL-4, and IL-7) also promote long-
term survival of resting T cells in vitro, while maintaining
the maturational state of these cells (43, 47). We hypothe-
sized that the signals delivered through cytokine receptors
alone may cause resting naive or memory T cells to over-
come the resistance to HDV-mediated transduction. To
examine this possibility, CD41 T cells were cultured in the
presence of various cytokines (Fig. 3) or in media alone for
4 d before challenge with HDV-IRES-EGFP. 5 d after in-
fection, robust GFP expression was observed in CD41 cells
that were cultured in IL-2, IL-4, IL-7, or IL-15, and a lower
but significant enhancement was detected in the presence
of IL-6 (Fig. 3 A), but none with TNF-a, IL-12, or IFN-g
(data not shown).
CD41 human T cells can be divided into naive and
memory subsets based on expression of RA and RO iso-
forms, respectively, of the CD45 molecule (48). These sub-
sets are phenotypically and functionally distinct and have
different activation requirements for antigen-specific stimu-
lation (48). In contrast to memory T cells, naive cells ex-
hibit few effector functions (e.g., cytokine production), are
less susceptible to activation induced cell death, and display
more robust proliferation in response to TCR-mediated
signals. To assess transduction efficiencies of naive versus
memory subsets of resting T cells stimulated with cyto-
kines, we purified naive T cells by removal of CD45RO1
Figure 2. Transduction of myeloid cells and lymphocytes other than a/b
T cells. To enrich for g/d1 T cells, a/b1 T cells were depleted by bead
sorting and PHA lines were established as described in Materials and
Methods. NK cells and B cells were positively sorted using antibodies to
CD16 and CD19 respectively. NK cells were activated with 1,000 U/ml
IL-2. B cells were activated as described in Materials and Methods. DC
cultures were established as described by Sallusto and Lanzavecchia (44).
Lymphocyte infections were done as described in Materials and Methods,
whereas macrophages and DCs were infected in the absence of polybrene
and at a lower MOI to prevent cytotoxicity induced by the viral superna-
tants. GFP was analyzed 2 wk after infection for g/d T cells and NK cells
(gated on CD32CD561 cells), and 5 d after infection for B cells. Quad-
rants were set according to uninfected control stainings. DC infections
were assessed 10 d after infection; cells were stained with PE-conjugated
anti-CD14 and PercP-conjugated HLA-DR; and GFP expression was
determined after gating on CD142 cells.1739 Unutmaz et al.
T cells using bead selection. The purified population (100%
RA1, 98% RO2) was prestimulated with IL-2, IL-4, or IL-7
and challenged with HDV-IRES.EGFP in the presence of
the same cytokines. Effective transduction of naive T cells
cultured with IL-4, IL-7, and, to a lesser extent, IL-2, was
observed (Fig. 3 B). In contrast, memory T cells were more
efficiently transduced when stimulated with IL-2 and IL-15
(see below and data not shown). Naive T cells cultured in
media alone did not display any GFP expression upon in-
fection (data not shown).
Transduction of resting CD81 cells was also achieved in
the presence of the same cytokines at similar or better effi-
ciencies than that observed with resting CD41 cells (Fig. 4).
Interestingly, this result contrasts those observed with trans-
duction of mitogen-activated CD81 T cells, which were
less efficiently transduced than CD41 T cell lines (see Fig. 2
C). It has been shown that TNF-a and IL-6, in the pres-
ence of IL-2, IL-4, or IL-7, can fully activate resting T cells
in an antigen-independent manner (42, 43). These cyto-
kine combinations had a small effect in increasing transduc-
tion efficiencies of CD41 or CD81 T cells, but greatly
boosted infection of the naive subset (Fig. 4).
The activation status of resting CD41 T cells stimulated
with individual cytokines was determined by staining in-
fected cells with antibodies specific for activation markers.
In each condition, .95% of GFP1 cells were negative for
the activation molecules CD69 or HLA-DR (data not
shown). Continuous BrdU labeling of cytokine-treated
resting cells for 8 d revealed that a total of 5–7% of cells
treated with IL-2 or IL-4 and z15% cells treated with IL-7
or IL-15 had entered the cell cycle during this period (data
not shown). We then wished to determine whether trans-
duction occurs only in the cells that have entered the cell
cycle. Therefore, resting T cells were cultured continu-
ously for 8 d with BrdU during cytokine stimulation and
HIV infection. Although the presence of BrdU drastically
reduced the efficiency of HIV infection (possibly due to
adverse effects during reverse transcription), more than half
of the cells that expressed GFP had not incorporated BrdU
(Fig. 5 A). This result shows that entry into the S phase of
the cell cycle is not required for infection of the cytokine-
stimulated resting T cells. In contrast to cytokine stimula-
tion, almost all of the T cells activated through the TCR
incorporated BrdU after 2 d of culture (Fig. 5 B). Although
few cytokine-stimulated T cells enter into the cell cycle,
especially in the presence of IL-7 and IL-15, we asked
whether MLV-derived vectors could also transduce these
cells. Cytokine-stimulated T cells were challenged with a
VSV-G–pseudotyped, GFP-expressing MLV-based vector,
pMX.EGFP. 4 d after infection, ,0.5% of the cytokine-
stimulated T cells and z1.5% of the TCR-stimulated T
cells expressed GFP, whereas nearly 100% of transformed
human T cell line, Jurkat, were transduced (data not shown).
These results clearly distinguish the efficiency of the HDV
in the transduction of primary human T cells.
Another important difference between cytokine-versus
TCR-mediated stimulation of resting T cells is that, in con-
trast to TCR triggering, cytokine signals do not cause differ-
entiation of naive T cells towards the memory phenotype
(43, 49). To confirm this, we cultured HDV-IRES.EGFP–
Figure 3. HDV-mediated transduction of both naive and memory
resting T cells cultured in the presence of various cytokines. Purified rest-
ing CD41 T cells were cultured for 4 d in media alone or with the fol-
lowing cytokines: IL-6 (400 U/ml), IL-2 (200 U/ml), IL-4 (20 ng/ml),
IL-7 (20 ng/ml), or IL-15 (10 ng/ml). Cells were infected with HDV-
IRES.GFP in the presence of cytokines for an additional 5 d and GFP ex-
pression was assessed. (A) GFP expression in resting T cells transduced in
the presence of cytokines. (B) GFP expression in CD45RA1RO2CD41
purified naive T cells transduced with HDV-IRES.EGFP.
Figure 4. Transduction efficiency of CD41 and CD81 resting T cells
stimulated with individual or combinations of cytokines. Resting T cells
were cultured and transduced with HDV-IRES.GFP as described in Fig.
3, with individual cytokines or in cytokine combinations (TNF-a was
used at 50 ng/ml). Percentage of GFP1 cells was determined by FACS®
analysis 5 d after infection.1740 HIV-1 Infects Cytokine-stimulated T Cells
infected resting T cells for 1 mo in the presence of IL-2, IL-4,
IL-7, or IL-15. These cells were then stained with CD45RO
antibody to discriminate memory (RO1) and naive (RO2) T
cells. The proportion of naive to memory T cells was compa-
rable to that in the starting population (z1:1) in all condi-
tions, although some bias was apparent in favor of memory or
naive T cells with IL-2 and IL-4, respectively (Fig. 6). The
HDV-transduced naive T cells also retained their phenotype
and IL-4 stimulation favored infection of these cells (Fig. 6).
To gain insight as to the level at which cytokines influ-
ence HIV infection of T cells, we challenged these cells
with HDV-IRES.EGFP in the absence of cytokines. 3 d
later cells were extensively washed to remove any remain-
ing virus and were cultured in the presence or absence of
cytokines for an additional 4 d. In the absence of cytokines,
there were very few GFP1 cells (,0.3%). However, addi-
tion of IL-2, IL-4, or IL-7 after infection revealed GFP ex-
pression in 1–3% of cells. We also infected resting cells in
the presence of IL-2 or IL-4 plus IFN-a, which is known
to block HIV infection at a preintegration step (50, 51). In-
deed, IFN-a completely blocked the transduction of rest-
ing T cells cultured with IL-2 or IL-4 (data not shown).
Addition of IFN-a to cultures after 4 d of transduction in
the presence of cytokines did not have any effect on GFP
expression, even after 10 d of culture (data not shown).
Taken together, these results suggest that HIV can enter
into a few resting T cells, but is arrested at a preintegration
stage of the viral life cycle. Cytokine signals are likely to
overcome this preintegration block.
Finally, we asked whether cytokine-activated T cells can
also be infected with replication-competent HIV-1, since
this may be an important mode of infection of T cells in vivo
and in the establishment of latency in resting cells. We used a
CCR5-tropic GFP-expressing replication-competent HIV-1
to infect cytokine-stimulated resting T cells under conditions
similar to those used for the HDV transduction. Infection of
cytokine-stimulated resting T cells was clearly observed 4 d
after challenge (Fig. 7). The GFP expression in the cytokine-
treated cells remained stable for .2 wk (data not shown).
However, the percentage of cells expressing GFP was lower
as compared with VSV-G–pseudotyped viruses. This could
be due to the relatively low titers of the R5 virus, which
limit the infection to an MOI of 1–2 compared with 10–20
for VSV-G viruses. It is also possible that the infection is in-
fluenced by the expression of CCR5 on cytokine-stimulated
versus TCR-activated T cells. Thus we examined CCR5
expression on resting T cells after culture in the presence of
Figure 5. Cell cycle entry and HDV
transduction of cytokine-stimulated resting
T cells. Resting T cells were cocultured in
the presence of cytokines and 10 mM BrdU
for 4 d and infected with HDV-EGFP for
an additional 4 d while being maintained in
continuous culture with fresh BrdU. T cells
stimulated with anti-CD3 plus anti-CD28
antibodies were cultured, 3 d after activa-
tion, with 10 mM BrdU for 2 d. Cells were
then permeabilized and stained with a PE-
conjugated anti-BrdU antibody. (A) GFP
expression and BrdU incorporation in cy-
tokine-stimulated T cells. (B) BrdU staining
of TCR-activated T cells.
Figure 6. Maintenance of naive phenotype of cytokine-stimulated and
HDV-EGFP–transduced resting T cells. HDV-EGFP–infected T cells
were cultured for 30 d in the presence of cytokines and stained with PE-
conjugated anti-CD45RO antibody. Numbers displayed above FACS®
analysis profiles are the percentage of positive cells in each quadrant.1741 Unutmaz et al.
cytokines. The expression of CCR5 was modestly upregu-
lated on IL-2 or IL-7 cultured resting T cells and more
strikingly in the presence of IL-15 (Fig. 8). The TCR-
mediated stimulation induced CCR5 expression in nearly
half of the cells (Fig. 8). The expression of CCR5 was ex-
clusively induced on the memory (CD45RO1) subset of T
cells (Fig. 8), consistent with the expression pattern of
CCR5 on PBMCs (52). The T-tropic HIV coreceptor
CXCR4 is expressed on all the naive T cells and on most
of the memory T cells (data not shown and reference 52);
however, we also observed an approximately fivefold in-
crease in CXCR4 expression levels in the presence of IL-4
(data not shown), similar to recent reports (53–55).
Use of the HDV System to Study Signaling Molecules in
Primary Human T Cells. One attractive feature of the ret-
roviral system is its potential use for dissecting signaling
pathways in primary cells. Because we are interested in co-
stimulatory signals mediated by the CD28 molecule, we
assessed the feasibility of performing a structure–function
analysis of this molecule by expressing mCD28 on human
T cells. CD41 or CD81 human T cells, expressing mCD28
(Fig. 9 A), were stimulated at suboptimal concentrations of
plate-bound anti-CD3, in the absence or presence of solu-
ble antibodies to hCD28 or mCD28, and cell proliferation
or IL-2 production were measured. T cells that expressed
mCD28 proliferated equally well in response to antibodies
against mCD28 or hCD28, in the presence of suboptimal
TCR cross-linking (Fig. 9 B). As a control, cells that stably
expressed a mutant form of mCD28 bearing a frame-shift
mutation in its cytoplasmic domain (at Asp188) displayed a
severely impaired proliferative response to anti-mCD28
(Fig. 9 B). It should be noted that the increase in prolifera-
tion observed with mutant mCD28 at higher concentra-
tions of anti-CD3 was also observed with anti-mCD4 anti-
body when mCD4-expressing T cells were used, and thus
may be the result of antibody-mediated clustering.
Figure 7. Replication-competent CCR5 tropic HIV-1 can infect cy-
tokine-activated resting T cells. Cytokine stimulation and HIV-1 infec-
tion was done as described in Fig. 4. Cells were fixed in 4% paraformalde-
hyde before FACS® analysis.
Figure 8. Expression of CCR5 on cytokine- or TCR-stimulated T
cells. Purified resting CD41 T cells were cultured with cytokines as de-
scribed in Fig. 3. Cells were stained with PE-conjugated anti-CCR5 and
FITC-conjugated anti-CD45RO antibodies.
Figure 9. Functional assessment of mCD28 expressed on human T
cells. (A) Expression of mCD28 in sorted T cells 2 wk after transduction
with HIV. (B) CD41 and CD81 human T cell lines transduced with
wild-type (w1) or cytoplasmic domain–deleted (Dcyto1) mCD28 were
stimulated 2 or 3 wk after the last activation with different concentrations
of plate-bound anti-CD3 in the presence or absence of 1 mg/ml soluble
anti-hCD28 or -mCD28 antibodies. Proliferation was measured after 2 d
by [3H]thymidine incorporation.1742 HIV-1 Infects Cytokine-stimulated T Cells
Since one of the hallmarks of CD28 costimulation is up-
regulation of IL-2 production (56), we also quantitated IL-2
synthesis in response to mCD28 costimulation. IL-2 secre-
tion was increased by up to 50-fold upon treatment of
CD41 T cell lines that expressed mCD28 with anti-mCD28
or -hCD28 (Fig. 10 A). As expected, mCD28 antibodies
did not upregulate IL-2 production in mCD28 nonex-
pressing cells or in cells expressing the cytoplasmic mutant
form of mCD28 (Fig. 10). Furthermore, the costimulation
through mCD28 was also partially resistant to Cyclosporin
A, similar to what is observed upon endogenous CD28 co-
stimulation (data not shown). To exclude the possibility of
heterodimer formation between mCD28 and hCD28, we
used CD81 T cell lines that stably express mCD28 but
have completely downregulated hCD28 because of re-
peated stimulations during in vitro culture. These cells pro-
duced high levels of IL-2 in response to mCD28 costimu-
lation, but, as expected, did not respond to treatment with
anti-hCD28 antibodies (Fig. 10 B). Similar studies were
also possible in cytokine-cultured resting T cells expressing
mCD28 (data not shown). These experiments clearly dem-
onstrate that it will be feasible to perform a thorough struc-
ture–function analysis of CD28 and possibly other signaling
molecules in primary human T lymphocytes.
Discussion
We have shown here, using an HDV system as well as
replication-competent HIV-1, that cytokines can stimulate
infection of resting T lymphocytes with these viruses. Previ-
ous studies have demonstrated a block in reverse transcription
of HIV-1 in resting T cells. Cytokine stimulation appears to
overcome this block, resulting in proviral integration and ex-
pression. This result may have major implications in under-
standing mechanisms of HIV-1 transmission and pathogenesis.
The HIV-1–based vector system described here can be
used for efficient and stable introduction of genes into all
subsets of activated human T cells as well as NK cells, mac-
rophages, DCs, and cytokine-stimulated resting T cells. Ef-
ficient transduction of both resting and activated cells was
achieved despite the deletion of the accessory genes vif, vpr,
vpu, and nef in the HIV vector. The removal of these acces-
sory genes avoids many unwanted effects in T cells. Indeed,
we did not observe any aberrant function of primary T cells
with regards to activation or proliferation after HDV-
mediated transduction. The use of a heterologous envelope
in pseudotypes and the deletion of accessory proteins im-
portant for virulence also makes it very unlikely that repli-
cation-competent recombinant virus can be generated. Us-
ing a sensitive assay (57), replication-competent viruses were
not detected in any of the infected lines.
We found transduction of mitogen-activated T cells
with HDV to be highly efficient; however, the transduc-
tion of CD41 T cells was always better than that of CD81
T cells. This may be due to the secretion of various inhibi-
tory factors such as IFNs by activated CD81 T cells and/or
the lack of factors that promote more efficient integration/
transcription of HIV. In contrast, cytokine-activated resting
CD81 T cells were infected very efficiently, even better than
CD41 T cells stimulated with cytokines or CD81 T cells
activated with mitogens (see Figs. 1 and 4). Additional
studies will be needed to identify host factors induced by
cytokine- versus TCR-mediated signaling that affect the
efficiency of HIV infection.
The Parameters for Infection of Resting T Cells with HIV.
The lentivirus subfamily of retroviruses, which includes
HIV-1, can infect nondividing cells because the HIV pre-
integration complex can exploit the cellular machinery to
allow transport into the nucleus (11–17). Efficient infection
of nondividing, terminally differentiated cells such as neu-
rons and macrophages or quiescent human hematopoietic
stem cells with HDVs has been reported (26, 27, 29, 33).
However, infection of quiescent T cells is blocked before
integration, probably due to incomplete reverse transcrip-
tion (18, 58–60) or failure to transport the viral preintegra-
tion complex to the nucleus (19, 21, 23, 61). Consistent
with these data, the HIV vector system described here does
not support expression of ectopic genes in resting human T
cells. However, by treating resting T cells with IL-2, IL-4,
IL-7, or IL-15 before virus challenge we were able to over-
come this block. Remarkably, these cytokines were equally
or even more effective in enhancing transduction of
CD45RA1 naive human T cells, especially when com-
bined with IL-6 and TNF-a. Although some resting T
cells progress through the cell cycle in response to cyto-
kine-mediated signals, this was not a prerequisite for the
infection of these cells (Fig. 5). Unlike TCR stimulation,
cytokine-mediated signals do not change the differentiation
state of the cells, such that naive T cells remain phenotypi-
cally naive and there is very little expression of activation
markers such as CD69 (with the exception of IL-15 stimu-
lation) and HLA-DR.
Introduction of exogenous genes into purified resting T
cells stimulated with cytokines may have applications in
clinical gene therapy where it may not be desirable or even
Figure 10. IL-2 production by costimulation through mCD28 ex-
pressed on human T cells. IL-2 production was measured by titrating su-
pernatants from cultures of CD41 or CD81 T cell lines that were stimu-
lated with anti-CD3 and anti-CD28. Supernatants were collected after 36 h
of stimulation and IL-2 was measured using the CTLL bioassay. 1 U of
IL-2 is defined as half-maximal proliferation of CTLL. (A) IL-2 produc-
tion by CD41 T cell lines. (B) IL-2 production by CD81 T cell lines that
are negative for hCD28 expression as determined by FACS® analysis.1743 Unutmaz et al.
possible (for example in some immunodeficiencies), to ac-
tivate the cells through the TCR. In addition, this system
can be used to address questions related to differentiation of
naive and memory T cells, by enabling genetic manipulation
of these cells in the absence of TCR-mediated activation.
Infection of cytokine-stimulated resting T cells may have
important physiological implications for HIV infection in
vivo. Cytokines have been reported to have dramatic ef-
fects on HIV replication in infected cells (45, 46, 62, 63).
In vivo, resting T cells that carry integrated provirus can be
detected even after highly active antiretroviral therapy, al-
beit at a very low frequency (23, 64–66). Interestingly, in a
recent study, the cytokine combination of IL-2, TNF-a,
and IL-6 was shown to induce expression of HIV in la-
tently infected resting T cells isolated from HIV-infected
individuals (67). However, it is not clear how resting T
cells in vivo become latently infected. It is generally
thought that memory T cells that may have been infected
while in an active state become quiescent before the virus
replicates and induces cytotoxicity (68). We have shown
that an R5 strain of HIV-1, with intact accessory genes, can
also infect cytokine-activated resting T cells. Our data and
those of others (Fig. 8 and references 52, 69) indicate that
CCR5 cell surface expression is upregulated in cytokine-
stimulated cells especially with IL-15 and at a lower level
with IL-2 or IL-7. Although this may facilitate infection by
R5 viruses, the effect of the cytokines clearly extends be-
yond viral entry in the resting T cells as demonstrated by
the HIV (VSV-G)–pseudotyped viruses. Therefore, it is
possible that infection with HIV-1 in vivo might occur in
resting T cells that are continuously exposed to cytokines at
sites of infection or in secondary lymphoid organs (45).
This may be important for the establishment of infection
and for viral pathogenesis. For example, infection of mac-
rophages or DCs with HIV-1 may induce innate immune
responses that result in production of the relevant cytokines
that promote infection of resting T cells. It will be neces-
sary to determine the efficiency of viral replication and
whether latency can be established in cytokine-stimulated
T cells. It is also tempting to speculate that cytokine-medi-
ated bystander activation of resting T cells may facilitate the
spread of the virus in vivo, thus contributing to the rapid
viral turnover rates (70, 71).
How do cytokine-induced signals allow transduction of
resting T cells? Identifying the molecular mechanisms by
which these signals enhance proviral establishment in rest-
ing T cells will help in understanding which host cofactors
are required during early stages of HIV infection. It is in-
teresting to note that, except for IL-6, the cytokines that
enhance the transduction of resting T cells all share the gc
chain in their receptors (72), suggesting a role for signals
delivered through this receptor component. It has been re-
ported that phosphorylation of components of the viral
preintegration complex by kinases, such as a virion-associ-
ated, mitogen-activated protein kinase, appears to enable
efficient transport of this complex to the nucleus (73).
Thus, signals delivered from the cytokine receptors may ac-
tivate host factors that are necessary for the translocation of
the preintegration complexes into the nucleus.
Our finding that primary human B cells are not detectably
transduced is intriguing. We did not assess whether the block
in B cells is at the level of integration or transcription. It may
be that primary B cells lack factors required for integration/
transcription and that these are induced in EBV-transformed
B cells. It is also possible that other signaling conditions may
permit efficient transduction of B cells. The infection of acti-
vated primary or transformed mouse T cells also was very in-
efficient (1–2%), whereas transduction using an MLV-based
retroviral system routinely transduced 10–60% of trans-
formed mouse T cells (data not shown). Although we did
not attempt to infect other primary mouse cell types, two
murine cell lines, NIH 3T3 fibroblasts and, interestingly, the
IL-2–dependent T cell line CTLL, were efficiently and sta-
bly transduced (data not shown). Elucidating these cell-type
specific restrictions or requirements for HDV-mediated
transduction may also be helpful in enhancing the suscepti-
bility of murine models of HIV infection (74).
Exploiting the HDV System to Perform Genetic Studies in
Primary T Cells. The ability to introduce genes into pri-
mary T lymphocytes should greatly assist the studies of T
cell differentiation and signal transduction in vitro. As a
proof of this concept we have shown that structure–func-
tion analysis of the costimulatory molecule CD28 is feasible
in primary lymphocytes and that mCD28 is functional in
delivering costimulatory signals in human T cells. Previ-
ously, these studies have been limited to transformed cell
lines, and it is likely that signaling pathways differ in subtle
but critical ways in primary T cells. Indeed, our ongoing
mutational analysis of CD28 cytoplasmic domain residues
has revealed differences when compared with similar stud-
ies performed in the transformed human Jurkat T cell line
(39) and identified functionally important regions of CD28
in primary T cells (Unutmaz, D., and S. Marmon, unpub-
lished data). Similar studies can readily be applied to other
signaling molecules expressed in primary lymphocytes or
myeloid cells. Furthermore, dominant negative or constitu-
tively active forms of intracellular molecules involved in
these pathways can be expressed and analyzed using the
HDV-IRES. GFP by sorting for GFP1 cells.
In conclusion, the HIV-1–based transduction system de-
scribed in this study will be a valuable tool in studying many
aspects of signal transduction in primary T cells and can have
potential applications in somatic gene therapy. Here we have
for the first time demonstrated that stimulation of resting T
cells with cytokines is sufficient for HIV-1 infection of these
cells while preserving their differentiation state. This finding
may have major implications in understanding the mecha-
nisms of virus infection of resting T cells in vivo.
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